Prime Therapeutics announces Ken Bodmer as chief financial officer

December 5, 2023

EAGAN, Minn. – Today, Prime Therapeutics LLC/Magellan Rx Management LLC (Prime/MRx) announces that it has appointed Ken Bodmer as chief financial officer (CFO), effective Dec. 4, 2023.

“Ken is an extraordinary leader with a deep understanding of the markets we serve and brings a unique blend of financial and operational expertise coupled with a proven track record of success” said Mostafa Kamal, president and chief executive officer at Prime. “I’ve always believed the role of CFO is about much more than managing the numbers. It’s about shaping the financial strategy of the company in ways that align with our core values and mission and Ken is the right person to do just that.”

Bodmer has more than 20 years of experience in business and financial leadership in both pharmacy benefit management and specialty pharmacy. Prior to joining Prime/MRx, Bodmer most recently served as both president and CFO at PANTHERx Rare, a rare-disease pharmacy focused on caring for patients with complex conditions. Prior to joining PANTHERx, Bodmer held leadership positions at CVS Health. His previous experience also includes both CFO and chief operating officer roles at Accredo, as well as key financial leadership roles at Medco (now Express Scripts) and Catamaran (now OptumRx).

“I am honored to join Prime/MRx at such a pivotal time in the health care industry,” said Bodmer. “Prime/MRx’s capabilities, reach and unique vision position the company to reimaging pharmacy management at a time when it matters more than ever. I’m looking forward to being part of that success.”

Bodmer completed his Master of Business Administration from Seton Hall University and his Bachelor of Science in Accounting from Villanova University. He is a member of the Financial Executive Institute, the Institute of Management Accountants, the American Institute of CPAs, and the Academy for Healthcare Management.

Related news

Press releases

April 11, 2024

Prime Therapeutics and Magellan Rx to present eight managed care pharmacy research studies at AMCP

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting

Press releases

March 13, 2024

Prime Therapeutics and Capital Rx Enter Into Transformative Strategic Alliance

Strategic alliance allows Prime to offer exclusive access to Capital Rx’s leading technology platform to achieve a higher standard of care, increase efficiency, improve experiences and provide the foundation for the next generation of integrated pharmacy care for the more than 50 million Americans served by Prime